Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

He, Chunjuan; Peng, Linna; Xing, Shishi; Li, Dandan; Wang, Li; Jin, Tianbo

doi:10.2147/pgpm.s316711

Cited by 2 publications

(2 citation statements)

References 30 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Usually, SNPs are employed to analyze the pharmacogenomic information in different populations. 3 , 4 “Pharmacogenomics” is an emerging approach to “precision medicine”. Pharmacogenomics plays a major part in precision medicine by “tailoring” the selection and dosing to the patient’s genetic features.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China

Wang¹,

Peng²,

Lu³

et al. 2021

PGPM

Self Cite

View full text Add to dashboard Cite

Background We aimed to enrich the pharmacogenomic information of a Blang population (BP) from Yunnan Province in China. Methods We genotyped 55 very important pharmacogene (VIP) variants from the PharmGKB database and compared their genotype distribution (GD) in a BP with that of 26 populations by the χ 2 test. The minor allele frequency (MAF) distribution of seven significantly different single-nucleotide polymorphisms (SNPs) was conducted to compare the difference between the BP and 26 other populations. Results Compared with the GD of 55 loci in the BP, among 26 studied populations, GWD, YRI, GIH, ESN, MSL, TSI, PJL, ACB, FIN and IBS were the top-10 populations, which showed a significantly different GD >35 loci. CHB, JPT, CDX, CHS, and KHV populations had a significantly different GD <20 loci. A GD difference of 27–34 loci was found between the BP and 11 populations (LWK, CEU, ITU, STU, PUR, CLM, GBR, ASW, BEB, MXL and PEL). The GD of five loci (rs750155 ( SULT1A1 ), rs4291 ( ACE ), rs1051298 ( SLC19A1 ), rs1131596 ( SLC19A1 ) and rs1051296 ( SLC19A1 )) were the most significantly different in the BP as compared with that of the other 26 populations. The genotype frequency of rs1800764 ( ACE ) and rs1065852 ( CYP2D6 ) was different in all populations except for PEL and LWK, respectively. MAFs of rs1065852 ( CYP2D6 ) and rs750155 ( SULT1A1 ) showed the largest fluctuation between the BP and SAS, EUR, AFR and AMR populations. Conclusion Our data can provide theoretical guidance for safe and efficacious personalized drug use in the Blang population.

show abstract

Section: Introductionmentioning

confidence: 99%

“…They also found that the allele frequency in this Tibetan population differed least from that of an East Asian population, and differed most from that of a North American population. 4 …”

Section: Introductionmentioning

confidence: 99%

Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China

Wang¹,

Peng²,

Lu³

et al. 2021

PGPM

Self Cite

View full text Add to dashboard Cite

show abstract

Very important pharmacogenetic variants landscape and potential clinical relevance in the Zhuang population from Yunnan province

Li,

Chang,

Yan

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The gradual evolution of pharmacogenomics has shed light on the genetic basis for inter-individual drug response variations across diverse populations. This study aimed to identify pharmacogenomic variants that differ in Zhuang population compared with other populations and investigate their potential clinical relevance in gene-drug and genotypic-phenotypic associations. A total of 48 variants from 24 genes were genotyped in 200 Zhuang subjects using the Agena MassARRAY platform. The allele frequencies and genotype distribution data of 26 populations were obtained from the 1000 Genomes Project, followed by a comparison and statistical analysis. After Bonferroni correction, significant differences in genotype frequencies were observed of CYP3A5 (rs776746), ACE (rs4291), KCNH2 (rs1805123), and CYP2D6 (rs1065852) between the Zhuang population and the other 26 populations. It was also found that the Chinese Dai in Xishuangbanna, China, Han Chinese in Beijing, China, and Southern Han Chinese, China showed least deviation from the Zhuang population. The Esan in Nigeria, Gambian in Western Division, The Gambia, and Yoruba in Ibadan, Nigeria exhibited the largest differences. This was also proved by structural analysis, Fst analysis and phylogenetic tree. Furthermore, these differential variants may be associated with the pharmacological efficacy and toxicity of Captopril, Amlodipine, Lisinopril, metoclopramide, and alpha-hydroxymetoprolol in the Zhuang population. Our study has filled the gap of pharmacogenomic information in the Zhuang population and has provided a theoretical framework for the secure administration of drugs in the Zhuang population.

show abstract

Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

Cited by 2 publications

References 30 publications

Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China

Genetic Polymorphisms of Very Important Pharmacogene Variants in the Blang Population from Yunnan Province in China

Very important pharmacogenetic variants landscape and potential clinical relevance in the Zhuang population from Yunnan province

Contact Info

Product

Resources

About